What Are the Side Effects of Antidepressant Medication?

If you have ever typed this question into a search bar late at night, you are in very good company. It is one of the most common things people want to know before they start an antidepressant and one of the most common reasons, they quietly stop taking one.

The honest answer is that antidepressants can cause real side effects, that most of them are manageable, and that a few of them deserve a much franker conversation than they usually get. Here is what the evidence shows:

The first few weeks

Most people who start an SSRI or SNRI notice something in the first one to two weeks: nausea, headache, jitteriness, changes in sleep, or a temporary dip in energy. These early effects are usually the body adjusting to a shift in serotonin signaling, and they typically fade. They are also, unfortunately, the point at which many people give up on a medication that might have worked well for them if they had made it to week six. The key takeaway here is to hang in there and give it a fair chance to see if it works.

Weight

This is the concern I hear most often, and the research is more reassuring than the internet suggests. The largest and best-designed study to date followed 183,118 adults across eight U.S. health systems, comparing eight commonly prescribed antidepressants over two years. At six months, compared with sertraline (Zoloft), escitalopram (Lexapro) was associated with about 0.41 kg more weight, paroxetine (Paxil) 0.37 kg, and duloxetine (Cymbalta) 0.34 kg. Fluoxetine (Prozac) was essentially the same as sertraline, and bupropion (Wellbutrin) was associated with slightly less weight, an advantage that held at one and two years.

In plain terms: the difference between the "worst" and "best" of these medications was roughly four pounds over six months. That is not nothing, but it is a long way from the dramatic weight gain many people fear. What struck me more about that study was a different number entirely only about one in three patients were still taking their original prescription at six months. Tolerability, not efficacy, is where most antidepressant treatment quietly fails.

Sexual side effects

This one has been consistently underreported, largely because older drug trials never asked about it systematically. Realistic estimates place sexual dysfunction somewhere between 30% and 50% of people taking SSRIs.

A 2026 meta-analysis of randomized placebo-controlled trials found that SSRIs roughly tripled the risk of difficulty reaching orgasm and modestly reduced sexual satisfaction. Because these were placebo-controlled, we can be reasonably confident this is a medication effect and not simply depression itself.

There is good news on the management side. A Cochrane review of 23 randomized trials found that sildenafil or tadalafil helped men with medication-related erectile difficulties, and that adding bupropion at adequate doses was the most promising strategy for women. Dose adjustment and switching agents are also reasonable options. None of these require you to simply endure the problem but all of them require telling your prescriber, which is the step most people skip.

A smaller number of people report sexual symptoms that persist after stopping the medication, sometimes called post-SSRI sexual dysfunction. European regulators formally acknowledged this in 2019. How often it happens is genuinely unresolved: one large cohort estimated to be roughly 1 in 216 treated patients, while other researchers argue the available data cannot support any reliable number yet. It appears to be uncommon. It is also real, and it deserves to be part of an informed conversation rather than dismissed.

Emotional blunting

This is the side effect patients describe most vividly and clinicians ask about least: feeling flat, muted, detached — not sad anymore, but not much of anything else either.

In a survey of 669 treated patients, 46% reported emotional blunting.⁷ A larger multinational study of 752 patients found that 45% believed their medication was dulling their emotions — and that 39% were considering stopping, or had already stopped, because of it.⁸

But here is where it gets genuinely interesting. In that same study, 56% of patients attributed the blunting to their depression rather than to the drug. Both can be true. Depression itself flattens emotion, and incomplete treatment leaves that flatness behind. Untangling the two is a clinical skill, not a guess.

We do have one clean piece of evidence that the medications contribute independently. Researchers gave escitalopram or placebo to 66 healthy volunteers — no depression to confound the picture — for three weeks.⁹ Memory and attention were unaffected. What changed was reward sensitivity: the escitalopram group became measurably less responsive to positive feedback. The same group also reported more difficulty reaching orgasm, which suggests both blunting and sexual side effects may share a common origin in how the brain processes reward.

An integrative way to think about all of this

Notice what every side effect above has in common: it is also a symptom of untreated depression. Depression changes weight. Depression suppresses libido. Depression flattens emotional range. So when someone tells me they feel numb on their medication, the useful question is never "is it the drug or the illness?" it is "which one, in what proportion, and how do we test that?"

That question has answers. Timing matters: symptoms that began within weeks of a dose change point toward the medication. Response matters: if depression is only partially treated, blunting may be residual illness rather than side effects. Metabolism matters, too, pharmacogenomic testing can reveal whether you clear a particular drug unusually slowly, which sometimes explains why a standard dose feels like a heavy one.

And a great deal that shapes tolerability has nothing to do with the prescription at all. Sleep quality, blood sugar stability, thyroid function, iron and B12 status, inflammation, alcohol intake, and physical activity all influence both how you feel and how well you tolerate medication. Checking those is not an alternative to psychiatric treatment. It is what makes psychiatric treatment work better at lower doses and lower doses generally mean fewer side effects.

Side effects are information. They tell us the dose is wrong, or the agent is wrong, or something underneath has not been addressed. They are rarely a reason to abandon treatment, and they are almost never something you should manage by stopping a medication on your own abrupt discontinuation causes its own set of problems.

If you are on an antidepressant and something feels off, say so out loud to whoever prescribes it. There are usually more options than you have been offered.

This article is for educational purposes and is not a substitute for individual medical advice. Do not start, stop, or change a prescribed medication without speaking with your prescriber.

References

1. Petimar J, Young JG, Yu H, et al. Medication-induced weight change across common antidepressant treatments: a target trial emulation study. Ann Intern Med. 2024;177(8):993-1003.

2. Zajecka J. SSRI-associated sexual dysfunction. Am J Psychiatry. 2006;163(9):1504-1509.

3. Sexual dysfunction associated with selective serotonin reuptake inhibitors in adults with depression: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2026. doi:10.1007/s00228-026-04011-z

4. Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2013;(5):CD003382.

5. Ben-Sheetrit J, Hermon Y, Birkenfeld S, Gutman Y, Csoka AB, Toren P. Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants. Ann Gen Psychiatry. 2023;22:15.

6. Healy D, Mangin D. Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence. Epidemiol Psychiatr Sci. 2024;33:e40.

7. Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant treatments: a survey among depressed patients. J Affect Disord. 2017;221:31-35.

8. Christensen MC, Fagiolini A, Florea I, Loft H, Cuomo A, Goodwin GM. Emotional blunting in patients with depression. Part I: clinical characteristics. Ann Gen Psychiatry. 2022;21:10.

9. Langley C, Armand S, Luo Q, et al. Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study. Neuropsychopharmacology. 2023;48:664-670.